56 County Durham, Darlington, North East schools named for free breakfast club pilot
Some 750 state schools with primary-aged children from every region of England have been selected to join the pilot, which is expected to run from April before a national rollout, including schools in County Durham, Darlington, Tyneside, Teesside, and Northumberland.
In total, there are 56 selected in the overall region.
The schools chosen for the trial are expected to offer a free breakfast to all pupils and at least 30 minutes of childcare before school.
The £7 million 'early adopters' scheme – which will test the delivery of the programme ahead of a wider national rollout in England – was announced at Labour's party conference in September.
Education Secretary Bridget Phillipson said the clubs would help to break the link 'between background and success' for families 'all over the country'.
'Alongside our plans to roll out school-based nurseries and get thousands more children school-ready, this Government is delivering the reforms needed to give every child, wherever they grow up, the best start in life,' she said.
Recommended reading:
5-year-old school girl diagnosed with rare bone cancer just weeks before Christmas
Campaign to turn County Durham farm into autism training centre attracts £300k grant
County Durham home with sunken gardens and original features on sale for £400,000
The headteachers' union welcomed the expansion of breakfast clubs, which some schools already run, but expressed concerns that funding would fall short of the cost.
'It will be crucial that these concerns are addressed before the programme is rolled out across the country to ensure that it does not place further pressure on already strained school budgets, and that children and families can fully reap the benefits,' said Paul Whiteman, general secretary of NAHT.
– Welbeck Academy
– Our Lady and St Anne's Catholic Primary School
– St Bernadette's Catholic Primary, Wallsend
– Langley First School
– Ivy Road Primary School
– St Bede's Catholic Primary School, South Shields
– Ashley Academy
– Stanhope Primary School
– Barnwell Academy
– Fatfield Academy
– St Leonard's Catholic Primary School, Silksworth
– St Joseph's Catholic Primary School, Sunderland
– Hudson Road Primary School
– Dame Dorothy Primary School
– Richard Avenue Primary School
– St Helen's Primary School
– Greatham CofE Primary School
– Pennyman Primary Academy
– St Bernadette's Catholic Primary School
– Skelton Primary School
– New Marske Primary School
– Overfields Primary School
– Lockwood Primary School
– Prior's Mill CofE Primary School
– Ingleby Mill Primary School
– Holy Trinity Rosehill CofE Voluntary Aided Primary School
– Ash Trees Academy
– Green Gates Academy
– St Joseph's Catholic Infant School, Birtley
– Cleves Cross Primary and Nursery School Academy
– Esh CofE (Aided) Primary School
– St Joseph's Catholic Primary School, Blackhall
– St Wilfrid's Catholic Primary School, Bishop Auckland
– Moorside Primary Academy
– Witton-le-Wear Primary School
– Middlestone Moor Academy
– Beamish Primary School
– Cockfield Primary School
– St Margaret's Church of England Primary School
– Prince Bishops Community Primary School
– Croft Community School
– High Coniscliffe CofE Primary School
– Morpeth Chantry Middle School
– Morpeth Newminster Middle School
– Malvin's Close Academy
– Croftway Academy
– Mickley First School
– NCEA Warkworth Church of England Primary School
– Amble Links Primary School
– Otterburn Primary School
– Cambo First School
– Shilbottle Primary School
– Bothal Primary School
– Hareside Primary School
– Chollerton Church of England Aided First School
– Holy Trinity Church of England First School
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
a day ago
- Medscape
Your Heart May Be Older Than You Think
Some people are said to have old souls. Some may have old hearts, too. Many Americans, particularly men with less education, lower income, and those from certain minority groups, have a 'heart age' that is much older than what the calendar may indicate, according to a new tool developed by researchers at Northwestern University and published on July 30 in JAMA Cardiology . Sadiya Khan, MD, a cardiologist at Feinberg School of Medicine, Northwestern University, in Chicago, and her colleagues wanted to simplify how clinicians communicate cardiovascular risk to patients, making it easier to interpret and understand. 'It's really important that risk is used in how we manage patients in preventive cardiology, but it can be really challenging to interpret the results,' she said. 'What does a 7.5% 10-year risk mean, for example?' Khan and her colleagues developed a tool to calculates a person's 'heart age' based on known cardiovascular risk factors such as blood pressure, cholesterol, diabetes, and smoking status. A 50-year-old with several high-risk factors could have a heart age that is equivalent to a 65-year-old with an optimal risk profile — a revelation that may help prompt them to take action on reducing their risk, Shah said. Risk age calculations are not new — the European Society of Cardiology's 2021 guidelines on prevention of cardiovascular disease allow such predictions, and they were also developed for the Framingham risk model. But Khan wanted to update the concept using the newer American Heart Association's PREVENT equations, and to take advantage of the growing public awareness of healthy aging. To evaluate the tool Khan's team tested it on more than 14,000 US adults aged 30-79 with no history of cardiovascular disease, using data from the National Health and Nutrition Examination Survey. On average, women in the survey had a chronological age of 51.3 years, but a heart age of 55.4 years, whereas for men the disparity was even greater: an average chronological age of 49.7 years but an average heart age of 56.7 years. Socioeconomic factors, such as education and income, also had a big effect on heart age. Among those with a high school education or less, more than one fifth of women, and nearly one third of men, had a heart age more than 10 years older than their true age. The gap was also significantly wider among members of certain racial and ethnic minorities. Black men had a heart age 8.5 years older than their true age vs 7.9 years older for Hispanic men, 6.7 years older for Asian men, and 6.4 years older for White men. The gaps were 6.2 years for Black women, 4.8 years for Hispanic women, 3.7 years for White women, and 2.8 years for Asian women, according to the researchers. 'I think some of the social factors that we highlighted where an individual's heart age might be older than their actual age, while not surprising, are helpful to see the health of the nation,' Khan said. The authors of an editorial accompanying the journal article wrote the new tool 'reframes risk in a more intuitive, personally relevant way' and combines epidemiology with behavioral psychology. 'This strategy taps into an intuitive grasp of time and aging, a concept more emotionally salient than a probabilistic 10-year risk estimate and may help bridge the persistent gap between knowledge of risk and engagement in health-promoting behavior,' they wrote. Presenting risk in this way could be particularly useful for younger people, whose lower absolute risk means they seldom think about ways they can improve their cardiovascular health, according to Khan and her colleagues. The team has created a free online version of the heart age calculator, but Khan said it is intended to be used in consultation with a physician. 'Our goal is not to have this be patient-facing but to have it be targeted to clinicians to help support that patient-clinician discussion,' she said. 'A tool like this is only as useful as the conversation that follows about the opportunities to promote or maintain heart health in optimizing your heart age.' Khan reported no relevant financial conflicts of interest.
Vogue
2 days ago
- Vogue
How to Navigate a Trauma Anniversary
A year after I was raped at 18, I sank down on the sidewalk, unable to keep going. I closed my eyes and didn't get up until a friend found me and helped me into bed, where I didn't speak or open my eyes for hours. I felt like I was trapped in time, unable to access relief until after the day had passed. A reaction like that, I would later learn, is common among survivors of sexual assault on their trauma anniversary—including those who no longer have an active PTSD diagnosis. Sara Schmidt, a clinical psychologist and expert in dialectical behavior therapy, says that on trauma anniversaries, her clients tend to 'start isolating themselves more, and sometimes they don't even realize they're doing it.' After 15 years of working through my own trauma, I wrote a book, Tell Me What You Like: An Honest Discussion of Sex and Intimacy After Sexual Assault, to help others do the same. Through personal healing and research into how to better cope with trauma's fallout, I've learned a lot about how to navigate trauma anniversaries. Here, a little of what I've gathered: What is a trauma anniversary? Trauma anniversaries mark the day a person's traumatic experience occurred. Not all people experience them the same way, but licensed professional counselor Kim Rippy explains that the powerful response a trauma anniversary can trigger comes from the brain's mechanisms for survival. Our minds pick out 'data points present in the initial trauma' and 'encode them as red flags for future experiences,' Rippy says. Our brains and bodies tend to remember dates—as well as smells, sounds, and visual cues—linked to a traumatic event in an attempt to protect us from future harm. For those whose trauma took the form of compounded, constant oppression, its aftermath will look a bit different. 'In marginalized groups, sometimes the trauma that they experience is more related to chronic invalidation,' observes Vibh Forsythe Cox, PhD, director of the Marsha M. Linehan Dialectical Behavior Therapy Training clinic. Though these folks can also experience trauma anniversaries, other triggers (or even just other dates, such as Mother's Day or Christmas) may affect them more deeply. What to do on the day Dr. Cox points out that no matter what time of year it is, you can start preparing for a trauma anniversary by connecting with a new therapist. If you already have a therapist, you can plan for additional sessions around the day. Otherwise, seeing loved ones can help us manage trauma anniversaries; or, if you don't have a strong social network nearby, Matthew Robinson, PhD, program director of the Trauma Continuum Program at McLean Hospital in Massachusetts, suggests taking advantage of Zoom, FaceTime, or even texting. 'It's helpful to be able to talk about things openly and honestly with someone who's going to get it,' he says, even if that person can't be there in person.
Yahoo
3 days ago
- Yahoo
North America Clinical Trials Market Forecast and Company Analysis Report 2025-2033 Featuring ICON, Wuxi AppTec, SGS, Syneos Health, PRA Health Sciences, Pfizer, IQVIA, and Medpace
The North America Clinical Trials Market is projected to grow from US$ 20.07 billion in 2024 to US$ 33.91 billion by 2033, registering a CAGR of 6.00% from 2025 to 2033. Key drivers include the increasing demand for novel treatments, rising prevalence of chronic conditions like COVID-19, diabetes, and various cancers, as well as supportive government R&D investments. The U.S. leads with robust infrastructure, top-notch research facilities, and significant technological advancements such as AI and decentralized trials. However, challenges persist with high operational costs and regulatory complexities. The market is vibrant, driven by rising clinical trial investments in sectors like oncology and enabled by innovative technologies, making it a promising field despite ongoing hurdles. North American Clinical Trials Market Dublin, July 29, 2025 (GLOBE NEWSWIRE) -- The "North America Clinical Trials Market Size and Forecast Report 2025-2033" report has been added to North America Clinical Trials Market is expected to reach US$ 33.91 billion by 2033 from US$ 20.07 billion in 2024, with a CAGR of 6.00% from 2025 to 2033. This is explained by longer clinical trial cycles, the demand for new treatments, and an increase in viral disorders as COVID-19 and diabetes, as well as advantageous government R&D spending. The growing need for novel medicines in a variety of therapeutic areas, including neurology, cardiology, and oncology, is the main factor propelling the North American clinical trials market's constant expansion. As a market leader, the United States enjoys the advantages of strong infrastructure, top-notch research facilities, and substantial investments in innovative healthcare. Drug development procedures are becoming faster and more efficient because to technological developments like big data, artificial intelligence, and decentralized clinical trials. Government financing and support for clinical research also contribute to the market's expansion. Nonetheless, the sector is still affected by issues including regulatory barriers, trouble recruiting patients, and expensive trial operating expenses. The market is nevertheless vibrant and is anticipated to continue evolving in spite of these market will expand quickly as a result of the growing number of clinical trials in North America, the pharmaceutical industry's expensive R&D costs, and the rising incidence of illnesses. Clinical trials for new or uncommon diseases are anticipated to benefit from the diverse disease profiles that are found to be growing with time due to the growing population in the North American region. Therefore, biopharmaceutical companies would be encouraged to increase their investment in clinical trials for a particular disease segment based on the number of patients with that of September 2022, there were over 13,323 ongoing clinical studies in various stages for cancer indications in the US, according to the US National Library of Medicine. Over the past few years, pharmaceutical corporations have likewise been spending more and more on research and development (R&D). This was mostly caused by a large number of patents expiring, which leaves many pharmaceutical companies with no choice except to create new medications. As a result, businesses are investing more in R&D to speed up the creation of medications through clinical trials, which will increase the market as a Drivers for the North America Clinical Trials Market Rising Prevalence of Chronic DiseasesOne of the main factors propelling the North American clinical trials market's expansion is the growing incidence of chronic illnesses including diabetes, cancer, and cardiovascular disorders. Clinical trials are being conducted by pharmaceutical corporations and research institutions due to the growing demand for new treatments and therapies as these diseases proliferate. These studies are essential for assessing the efficacy and security of possible treatments. Clinical trials are crucial for expanding medical knowledge and enhancing patient outcomes since chronic diseases frequently call for long-term management and innovative treatment choices. An older population, which is more likely to suffer chronic illnesses, supports this trend and increases the need for ongoing clinical research and innovative therapy in TechnologyTechnological developments are drastically changing the clinical trials environment in North America. Clinical study design, management, and execution are being improved by emerging technologies including artificial intelligence (AI), machine learning (ML), and big data analytics. These technologies aid in the real-time analysis of massive volumes of trial data, the more accurate identification of qualified applicants, and the prediction of patient outcomes. They thereby shorten trial durations, cut down on mistakes, and enhance decision-making. AI and ML are also being used to remotely monitor patient adherence and optimize protocol design, which lowers costs and increases trial efficiency. These developments make technology a potent growth engine in the dynamic clinical research environment since they not only speed up drug development but also increase trial success Investment in Oncology ResearchOne of the main factors propelling the growth of the clinical trials market is the rising incidence of cancer in North America, which has greatly increased funding for oncology research. The creation of novel cancer treatments is receiving a significant amount of support from public and private institutions as well as pharmaceutical firms. Clinical trials focusing on cancer, such as immunotherapies, targeted medicines, and personalized medical methods, have increased as a result of this financial boom. Research efforts have been sped up by the need to find efficient treatments and raise survival rates, which has prompted quicker trial initiation and increased cooperation between sponsors and research institutes. Since cancer is still one of the top causes of mortality, the region's clinical trial activity is growing in scope and size due to the strong emphasis on oncology in the North America Clinical Trials Market High Operational CostsOne major issue facing the clinical trials sector in North America is high operating costs. Significant costs are associated with conducting a clinical trial, such as hiring highly qualified personnel, investing in cutting-edge technology, building out the facility, adhering to regulations, and continuously gathering and tracking data. Complex trial designs, multi-site coordination, and longer study durations can all result in further increases in these expenses. Financial limitations can make it difficult for smaller biotech companies and research institutes to start or continue trials, frequently forcing them to rely on collaborations or outside funding. There is still a lot of pressure to strike a balance between cost effectiveness, data quality, and legal requirements. The cost of trials only goes up as they get more creative and customized, which is a major obstacle to larger research and development ComplexitiesOne of the biggest obstacles facing the clinical trials sector in North America is the complexity of regulations. To guarantee the safety and effectiveness of novel medications and therapies, organizations such as the U.S. Food and Drug Administration (FDA) implement strict and ever-changing regulations. Although these rules are necessary, following them can cause delays in trial approvals and raise compliance expenses dramatically. The procedure, which can be time- and resource-intensive, entails thorough documentation, ethical evaluations, and adherence to stringent criteria. Conducting multinational or multi-site studies also adds another level of complexity because different regulatory requirements in different locations need to be carefully maintained. These elements may cause delays in the start of trials, cause schedule disruptions, and increase the administrative load on sponsors and research institutions. Key Players Analyzed: Overviews, Key Persons, Recent Developments, Revenue ICON Plc Wuxi AppTec SGS SA Syneos Health PRA Health Sciences Inc Pfizer Inc. IQVIA Medpace Stryker Corporation Zimmer Biomet Holdings Orthofix Medical Inc. NuVasive Inc. Globus Medical Inc. Bejo Zaden BV Corteva Agriscience Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $20.07 Billion Forecasted Market Value (USD) by 2033 $33.91 Billion Compound Annual Growth Rate 6.0% Regions Covered North America Key Topics Covered: 1. Introduction2. Research & Methodology2.1 Data Source2.1.1 Primary Sources2.1.2 Secondary Sources2.2 Research Approach2.2.1 Top-Down Approach2.2.2 Bottom-Up Approach2.3 Forecast Projection Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. North America Clinical Trials Market5.1 Historical Market Trends5.2 Market Forecast6. Market Share6.1 By Phases6.2 By Indications6.3 By Study Designs6.4 By Countries7. Phases7.1 Phase 17.2 Phase 27.3 Phase 37.4 Phase 48. Indications8.1 Autoimmune/Inflammation8.2 Pain management8.3 Oncology8.4 CNS Condition8.5 Diabetes8.6 Obesity8.7 Cardiovascular8.8 Others9. Study Designs9.1 Interventional9.2 Observational9.3 Expanded Access10. Countries10.1 United States10.2 Canada10.3 Mexico10.4 Rest of North America11. Porter's Five Forces Analysis11.1 Bargaining Power of Buyers11.2 Bargaining Power of Suppliers11.3 Degree of Rivalry11.4 Threat of New Entrants11.5 Threat of Substitutes12. SWOT Analysis12.1 Strength12.2 Weakness12.3 Opportunity12.4 Threat13. Key Players AnalysisFor more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment North American Clinical Trials Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
